|
1
|
Khan SA, Davidson BR, Goldin RD, Heaton N,
Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD,
Thillainayagam AV, et al British Society of Gastroenterology, :
Guidelines for the diagnosis and treatment of cholangiocarcinoma:
An update. Gut. 61:1657–1669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bhudhisawasdi V, Talabnin C, Pugkhem A,
Khuntikeo N, Seow OT, Chur-in S, Pairojkul C and Wongkham S:
Evaluation of postoperative adjuvant chemotherapy for intrahepatic
cholangiocarcinoma patients undergoing R1 and R2 resections. Asian
Pac J Cancer Prev. 13:169–174. 2012.PubMed/NCBI
|
|
3
|
Dhanasekaran R, Hemming AW, Zendejas I,
George T, Nelson DR, Soldevila-Pico C, Firpi RJ, Morelli G, Clark V
and Cabrera R: Treatment outcomes and prognostic factors of
intrahepatic cholangiocarcinoma. Oncol Rep. 29:1259–1267. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nagino M, Ebata T, Yokoyama Y, Igami T,
Sugawara G, Takahashi Y and Nimura Y: Evolution of surgical
treatment for perihilar cholangiocarcinoma: A single-center 34-year
review of 574 consecutive resections. Ann Surg. 258:129–140. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nagorney DM, Donohue JH, Farnell MB,
Schleck CD and Ilstrup DM: Outcomes after curative resections of
cholangiocarcinoma. Arch Surg. 128:871–879. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thongprasert S: The role of chemotherapy
in cholangiocarcinoma. Ann Oncol. 16 (Suppl 2):ii93–ii96. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fodale V, Pierobon M, Liotta L and
Petricoin E: Mechanism of cell adaptation: When and how do cancer
cells develop chemoresistance? Cancer J. 17:89–95. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: an evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pelicano H, Carney D and Huang P: ROS
stress in cancer cells and therapeutic implications. Drug Resist
Updat. 7:97–110. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gorrini C, Harris IS and Mak TW:
Modulation of oxidative stress as an anticancer strategy. Nat Rev
Drug Discov. 12:931–947. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guan J, Lo M, Dockery P, Mahon S, Karp CM,
Buckley AR, Lam S, Gout PW and Wang YZ: The xc-cystine/glutamate
antiporter as a potential therapeutic target for small-cell lung
cancer: Use of sulfasalazine. Cancer Chemother Pharmacol.
64:463–472. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Montero AJ, Diaz-Montero CM, Deutsch YE,
Hurley J, Koniaris LG, Rumboldt T, Yasir S, Jorda M, Garret-Mayer
E, Avisar E, et al: Phase 2 study of neoadjuvant treatment with
NOV-002 in combination with doxorubicin and cyclophosphamide
followed by docetaxel in patients with HER-2 negative clinical
stage II–IIIc breast cancer. Breast Cancer Res Treat. 132:215–223.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Trachootham D, Alexandre J and Huang P:
Targeting cancer cells by ROS-mediated mechanisms: A radical
therapeutic approach? Nat Rev Drug Discov. 8:579–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu JM, Pan F, Li L, Liu OR, Chen Y, Xiong
XX, Cheng K, Yu SB, Shi Z, Yu CH, et al: Piperlongumine selectively
kills glioblastoma multiforme cells via reactive oxygen species
accumulation dependent JNK and p38 activation. Biochem Biophys Res
Commun. 437:87–93. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thongsom S, Suginta W, Lee KJ, Choe H and
Talabnin C: Piperlongumine induces G2/M phase arrest and apoptosis
in cholangiocarcinoma cells through the ROS-JNK-ERK signaling
pathway. Apoptosis. 22:1473–1484. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Raj L, Ide T, Gurkar AU, Foley M, Schenone
M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, et al:
Selective killing of cancer cells by a small molecule targeting the
stress response to ROS. Nature. 475:231–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maines MD and Abrahamsson PA: Expression
of heme oxygenase-1 (HSP32) in human prostate: normal,
hyperplastic, and tumor tissue distribution. Urology. 47:727–733.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Goodman AI, Choudhury M, da Silva JL,
Schwartzman ML and Abraham NG: Overexpression of the heme oxygenase
gene in renal cell carcinoma. Proc Soc Exp Biol Med. 214:54–61.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yin H, Fang J, Liao L, Maeda H and Su Q:
Upregulation of heme oxygenase-1 in colorectal cancer patients with
increased circulation carbon monoxide levels, potentially affects
chemotherapeutic sensitivity. BMC Cancer. 14:4362014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kongpetch S, Kukongviriyapan V, Prawan A,
Senggunprai L, Kukongviriyapan U and Buranrat B: Crucial role of
heme oxygenase-1 on the sensitivity of cholangiocarcinoma cells to
chemotherapeutic agents. PLoS One. 7:e349942012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kongpetch S, Puapairoj A, Ong CK,
Senggunprai L, Prawan A, Kukongviriyapan U, Chan-On W, Siew EY,
Khuntikeo N, Teh BT, et al: Haem oxygenase 1 expression is
associated with prognosis in cholangiocarcinoma patients and with
drug sensitivity in xenografted mice. Cell Prolif. 49:90–101. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Furfaro AL, Piras S, Passalacqua M,
Domenicotti C, Parodi A, Fenoglio D, Pronzato MA, Marinari UM,
Moretta L, Traverso N, et al: HO-1 up-regulation: A key point in
high-risk neuroblastoma resistance to bortezomib. Biochim Biophys
Acta. 1842:613–622. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lv X, Song DM, Niu YH and Wang BS:
Inhibition of heme oxygenase-1 enhances the chemosensitivity of
laryngeal squamous cell cancer Hep-2 cells to cisplatin. Apoptosis.
21:489–501. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sripa B, Leungwattanawanit S, Nitta T,
Wongkham C, Bhudhisawasdi V, Puapairoj A, Sripa C and Miwa M:
Establishment and characterization of an opisthorchiasis-associated
cholangiocarcinoma cell line (KKU-100). World J Gastroenterol.
11:3392–3397. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sripa B, Seubwai W, Vaeteewoottacharn K,
Sawanyawisuth K, Silsirivanit A, Kaewkong W, Muisuk K, Dana P,
Phoomak C, Lert-Itthiporn W, et al: Functional and genetic
characterization of three cell lines derived from a single tumor of
an Opisthorchis viverrini-associated cholangiocarcinoma patient.
Hum Cell. Mar 23–2020.(Epub ahead of print). doi:
10.1007/s13577-020-00334-w. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Voigt W: Sulforhodamine B assay and
chemosensitivity. Methods Mol Med. 110:39–48. 2005.PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Labbé RF, Vreman HJ and Stevenson DK: Zinc
protoporphyrin: A metabolite with a mission. Clin Chem.
45:2060–2072. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang S, Avery JE, Hannafon BN, Lind SE and
Ding WQ: Zinc protoporphyrin suppresses cancer cell viability
through a heme oxygenase-1-independent mechanism: The involvement
of the Wnt/β-catenin signaling pathway. Biochem Pharmacol.
85:1611–1618. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu YS, Li HS, Qi DF, Zhang J, Jiang XC,
Shi K, Zhang XJ and Zhang XH: Zinc protoporphyrin IX enhances
chemotherapeutic response of hepatoma cells to cisplatin. World J
Gastroenterol. 20:8572–8582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cheng CC, Guan SS, Yang HJ, Chang CC, Luo
TY, Chang J and Ho AS: Blocking heme oxygenase-1 by zinc
protoporphyrin reduces tumor hypoxia-mediated VEGF release and
inhibits tumor angiogenesis as a potential therapeutic agent
against colorectal cancer. J Biomed Sci. 23:182016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Martin D, Rojo AI, Salinas M, Diaz R,
Gallardo G, Alam J, Galarreta CM and Cuadrado A: Regulation of heme
oxygenase-1 expression through the phosphatidylinositol
3-kinase/Akt pathway and the Nrf2 transcription factor in response
to the antioxidant phytochemical carnosol. J Biol Chem.
279:8919–8929. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen HH, Chen YT, Huang YW, Tsai HJ and
Kuo CC: 4-Ketopinoresinol, a novel naturally occurring ARE
activator, induces the Nrf2/HO-1 axis and protects against
oxidative stress-induced cell injury via activation of PI3K/AKT
signaling. Free Radic Biol Med. 52:1054–1066. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee HN, Jin HO, Park JA, Kim JH, Kim JY,
Kim B, Kim W, Hong SE, Lee YH, Chang YH, et al: Heme oxygenase-1
determines the differential response of breast cancer and normal
cells to piperlongumine. Mol Cells. 38:327–335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang F, Mao Y, You Q, Hua D and Cai D:
Piperlongumine induces apoptosis and autophagy in human lung cancer
cells through inhibition of PI3K/Akt/mTOR pathway. Int J
Immunopathol Pharmacol. 28:362–373. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou L, Li M, Yu X, Gao F and Li W:
Repression of hexokinases II-mediated glycolysis contributes to
piperlongumine-induced tumor suppression in non-small cell lung
cancer cells. Int J Biol Sci. 15:826–837. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yokoi K, Kobayashi A, Motoyama H, Kitazawa
M, Shimizu A, Notake T, Yokoyama T, Matsumura T, Takeoka M and
Miyagawa SI: Survival pathway of cholangiocarcinoma via AKT/mTOR
signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
Oncol Rep. 39:843–850. 2018.PubMed/NCBI
|
|
38
|
Yoon H, Min JK, Lee JW, Kim DG and Hong
HJ: Acquisition of chemoresistance in intrahepatic
cholangiocarcinoma cells by activation of AKT and extracellular
signal-regulated kinase (ERK)1/2. Biochem Biophys Res Commun.
405:333–337. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yothaisong S, Dokduang H, Techasen A,
Namwat N, Yongvanit P, Bhudhisawasdi V, Puapairoj A, Riggins GJ and
Loilome W: Increased activation of PI3K/AKT signaling pathway is
associated with cholangiocarcinoma metastasis and PI3K/mTOR
inhibition presents a possible therapeutic strategy. Tumour Biol.
34:3637–3648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen HH, Chen YT and Huang YW:
4-Ketopinoresinol, a novel naturally occurring ARE activator,
induces the Nrf2/HO-1 axis and protects against oxidative
stress-induced cell injury via activation of PI3K/AKT signaling.
Free Radic Biol Med. 52:1054–1066. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Arlt A, Gehrz A, Muerkoster S, Vorndamm J,
Kruse ML, Folsch UR and Schäfer H: Role of NF-kappaB and Akt/PI3K
in the resistance of pancreatic carcinoma cell lines against
gemcitabine-induced cell death. Oncogene. 22:3243–3251. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Huang WC and Hung MC: Induction of Akt
activity by chemotherapy confers acquired resistance. J Formos Med
Assoc. 108:180–194. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Leelawat K, Narong S, Udomchaiprasertkul
W, Leelawat S and Tungpradubkul S: Inhibition of PI3K increases
oxaliplatin sensitivity in cholangiocarcinoma cells. Cancer Cell
Int. 9:32009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Berberat PO, Dambrauskas Z, Gulbinas A,
Giese TG, Kunzli B, Autschbach F, Meuer S, Büchler MW and Friess H:
Inhibition of heme oxygenase-1 increases responsiveness of
pancreatic cancer cells to anticancer treatment. Clin Cancer Res.
11:3790–3798. 2005. View Article : Google Scholar : PubMed/NCBI
|
